Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS.

Am J Hematol. 2013 Jul;88(7):566-70. doi: 10.1002/ajh.23454. Epub 2013 May 30.

2.

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Tallman MS, Gore SD; Eastern Cooperative Oncology Group (ECOG) and North American Leukemia intergroup.

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

3.

IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients.

Yang YT, Hou HA, Liu CY, Lin CC, Chou WC, Lee FY, Liu MC, Liu CW, Tang JL, Yao M, Li CC, Kuo YY, Huang SY, Ko BS, Chen CY, Hsu SC, Lin CT, Wu SJ, Tsay W, Chen YC, Tien HF.

Am J Hematol. 2014 Sep;89(9):E142-9. doi: 10.1002/ajh.23765. Epub 2014 Jun 19.

4.

Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.

van Spronsen MF, Ossenkoppele GJ, Holman R, van de Loosdrecht AA.

Eur J Cancer. 2014 Dec;50(18):3198-205. doi: 10.1016/j.ejca.2014.09.016. Epub 2014 Oct 28.

PMID:
25454415
5.

Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.

Cluzeau T, Mounier N, Karsenti JM, Richez V, Legros L, Gastaud L, Garnier G, Re D, Montagne N, Gutnecht J, Gabriel Fuzibet J, Auberger P, Raynaud S, Cassuto JP.

Am J Hematol. 2013 Sep;88(9):780-3. doi: 10.1002/ajh.23509. Epub 2013 Jul 23.

6.

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R; MDS Clinical Research Consortium.

Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.

7.

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.

Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M.

Am J Hematol. 2013 Mar;88(3):198-200. doi: 10.1002/ajh.23371. Epub 2013 Jan 24.

8.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD.

Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

9.

Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation).

Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173.

10.

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.

Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A.

J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.

PMID:
23796988
11.

Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.

Lee YJ, Park SW, Lee IH, Ahn JS, Kim HJ, Chung JS, Shin HJ, Lee WS, Lee SM, Joo YD, Kim H, Lee HS, Kim YS, Cho YY, Moon JH, Sohn SK.

Ann Hematol. 2016 Oct;95(11):1795-804. doi: 10.1007/s00277-016-2759-y. Epub 2016 Aug 17.

PMID:
27530461
12.

Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.

Garcia-Manero G.

Am J Hematol. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102. Review.

13.

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, Beguin Y, N'guyen S, Bories P, Blaise D, Cornillon J, Clavert A, Mohty M, Huynh A, Thiébaut-Bertrand A, Vigouroux S, Duhamel A, Yakoub-Agha I.

Transplantation. 2015 Aug;99(8):1672-80. doi: 10.1097/TP.0000000000000649.

PMID:
25769079
14.

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I.

J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.

15.

Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.

Savic A, Marisavljevic D, Kvrgic V, Stanisavljevic N.

Acta Haematol. 2014;131(4):231-8. doi: 10.1159/000354840. Epub 2013 Dec 11.

PMID:
24335346
16.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.

de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, Symeonidis A, Sanz G, Hellström-Lindberg E, Cermák J, Germing U, Stauder R, Georgescu O, MacKenzie M, Malcovati L, Holm MS, Almeida AM, Mądry K, Slama B, Guerci-Bresler A, Sanhes L, Beyne-Rauzy O, Luño E, Bowen D, de Witte T.

Br J Haematol. 2015 Aug;170(3):372-83. doi: 10.1111/bjh.13450. Epub 2015 Apr 24.

PMID:
25907546
17.

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler C.

J Clin Oncol. 2013 Jul 20;31(21):2662-70. doi: 10.1200/JCO.2012.46.8652. Epub 2013 Jun 24.

18.

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF.

Cancer. 2012 May 15;118(10):2659-64. doi: 10.1002/cncr.26567. Epub 2011 Sep 28.

19.

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.

Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.

Br J Haematol. 2014 Oct;167(1):100-9. doi: 10.1111/bjh.12994. Epub 2014 Jun 30.

PMID:
24976502
20.

Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Damaj G, Mohty M, Robin M, Michallet M, Chevallier P, Beguin Y, Nguyen S, Bories P, Blaise D, Maillard N, Rubio MT, Fegueux N, Cornillon J, Clavert A, Huynh A, Adès L, Thiébaut-Bertrand A, Hermine O, Vigouroux S, Fenaux P, Duhamel A, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1349-55. doi: 10.1016/j.bbmt.2014.05.010. Epub 2014 May 14.

Supplemental Content

Support Center